老年支气管扩张合并急性感染的病原菌及其耐药性研究

中国临床药理学与治疗学 ›› 2012, Vol. 17 ›› Issue (8): 914-918.

老年支气管扩张合并急性感染的病原菌及其耐药性研究

宋秀杰, 路聪哲, 方庭正, 韩文杰, 芮萌, 欧敏

海军总医院干部呼吸科,北京 100048

收稿日期:2012-06-20 修回日期:2012-07-15 出版日期:2012-08-26 发布日期:2012-08-14
作者简介:宋秀杰,女,博士,主治医师,研究方向:肺部感染及抗生素耐药。Tel: 010-66958502 E-mail: sxj_sxj@163.com

Pathogens and drug resistant rate analysis of aged of bronchiectasis patients in an acute exacerbation

SONG Xiu-jie, LU Cong-zhe, FANG Ting-zheng, HAN Wen-jie, RUI Meng, OU Min

Department of Cadre Respiratory Diease, Navy General Hospital,Beijing 100048,China

Received:2012-06-20 Revised:2012-07-15 Online:2012-08-26 Published:2012-08-14

摘要/Abstract

摘要： 目的: 了解老年支气管扩张患者急性感染的病原学分布及药敏情况, 指导临床抗菌药物的使用。方法: 对2000—2012 年本院呼吸科104份老年支气管扩张急性感染患者的痰标本进行细菌培养及药敏试验。结果: 150 例痰标本分离出致病菌107 株, 其中革兰氏阴性菌 87 株, 占81%, 排在前 3 位的致病菌分别是铜绿假单胞菌( 35%),肺炎克雷伯菌( 14% ),鲍曼不动杆菌(11%)。革兰氏阳性球菌8株(7%),真菌12株(11%)。药敏实验显示所分离出的革兰氏阴性杆菌对哌拉西林-他唑巴坦, 第 3、4 代头孢菌素及碳青霉烯类、多粘菌素等抗菌药物敏感性较高。结论: 老年支气管扩张急性感染的病原菌分布以革兰氏阴性杆菌为主, 铜绿假单胞菌排在首位,经验治疗时建议选用哌拉西林/他唑巴坦、头孢三代、四代或碳青霉烯类药物。

关键词: 老年支气管扩张, 急性加重, 病原菌, 药敏实验

Abstract: AIM: To learn the situation of pathogens distribution and drug sensitivity in aged bronchiectasis in an acute exacerbation.METHODS: 150 samples of sputum bacteria culture and drug sensitivity tests from 104 aged patients were performed in our hospital from 2000 to 2012.RESULTS: 107 isolates isolated from 150 sputum samples, among them there were 87 isolates of gram-negative bacillus (81%). The most common Gram-negative bacillus isolated were Pseudomonas aeruginosa(35%), Klebsiella pneumoniae(14% ), Acinetobacter baumannii(11%). There were 8 strains of gram-positive bacteria(7%),12 strains of fungi(11%). Piperacillin/tabazotani, three generation cephalosporin,four generation cephalosporin carbapenem,and quinolone has better antimicrobial activity against. gram-negative bacillus.CONCLUSION: The main pathogen of aged bronchiectasis in an acute exacerbation was gram negative bacteria, pseudomonas aeruginosa was the most commen pathogens among them. Piperacillin/tabazotani, three generation cephalosporin, four generation cephalosporin, carbapenem should be recommended to treat these aged bronchiectasis patients.

Key words: Aged bronchiectasis, Acute exacerbations, Pathogen, Drug sensitivity test

中图分类号:

宋秀杰, 路聪哲, 方庭正, 韩文杰, 芮萌, 欧敏. 老年支气管扩张合并急性感染的病原菌及其耐药性研究[J]. 中国临床药理学与治疗学, 2012, 17(8): 914-918.

SONG Xiu-jie, LU Cong-zhe, FANG Ting-zheng, HAN Wen-jie, RUI Meng, OU Min. Pathogens and drug resistant rate analysis of aged of bronchiectasis patients in an acute exacerbation[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2012, 17(8): 914-918.

参考文献

[1] Rademacher J, Welte T.Bronchiectasis-diagnosis and treatment[J]. Dtsch Arztebl Int, 2011, 108(48): 809-815.
[2] Rademacher J, Welte T.Bronchiectasis-diagnosis and treatment[J]. Dtsch Arztebl Int, 2011, 108(48): 809-815.
[3] O'Donnell, A. E. Bronchiectasis[J].. Chest.2008:134;815-823.
[4] Barker AF. Bronchiectasis[J]. NEJM 2002;346(18):1383-93.
[5] Emmons EE. Bronchiectasis from WebMD. 1996-2008. Available online. http://emedicine.medscape.com/article/296961-overview. Accessed July 30th, 2009.
[6] 霍海燕, 萧淑华, 郭苏.104例支气管扩张急性感染的病原学检测及药敏分析[J].黑龙江医学,2007,31(4):286-287.
[7] 张腊梅,朱华.支气管扩张合并感染患者病原学及药敏分析[J].现代医药卫生,2011,27(20):3065-3066.
[8] 王丽娟,106例老年支气管扩张症患者感染加重期病原菌与耐药性分析[J].吉林医学,2011,32(5).
[9] Rosen MJ. Chronic cough due to bronchiectasis: ACCP evidence-based clinical practice guidelines[J]. Chest,2006;129(1suppl):122S-131S.
[10] Davies G, Wells AU, Doffman S, et al. The effect of Pseudomonas aeruginosa on pulmonary function in patients with bronchiectasis[J]. Eur Respir J,2006,28(5):974-979.
[11] Loebinger MR, Wells AU, Hansell DM,et al. Mortality in bronchiectasis: a long-term study assessing the factors influencing survival[J]. Eur Respir J,2009,34(4): 843-849.
[12] Martínez-García MA, Soler-Cataluña JJ, Perpiñá-Tordera M, et al. Factors associated with lung function decline in adult patients with stable non-cystic fibrosis bronchiectasis[J]. Chest, 2007, 132(5):1565-1572.
[13] Anwar GA,Bourke SC, Afolabi G,et al. Effects of long-term low-dose azithromycin in patients with non-CF bronchiectasis[J]. Respir Med, 2008,102(10):1494-1496.
[14] Figueiredo Bde C, Ibiapina Cda C. The Role of macrolides in noncystic fibrosis bronchiectasis[J]. Pulm Med,2011, Epub 2011 Sep 5.
[15] Scheinberg P, Shore E. A pilot study of the safety and efficacy of tobramycin solution for inhalation in patients with severe bronchiectasis[J].Chest,2005, 127(4):1420-1426.
[16] Drobnic ME, Suñé P, Montoro JB, et al. Inhaled tobramycin in non-cystic fibrosis patients with bronchiectasis and chronic bronchial infection with Pseudomonas aeruginosa[J]. Ann Pharmacother,2005,39(1): 39-44.
[17] Antoniu SA, Trofor AC. Inhaled gentamicin in non-cystic fibrosis bronchiectasis:effects of long-term therapy[J]. Expert Opin Pharmacother, 2011,12(7): 1191-1194.